COPD trials recruiting in Indiana

All COPD trials nationally

Cities in Indiana

Recruiting trials in Indiana

• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Indiana: Valparaiso
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
  NCT06883305 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Indiana: Munster
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
  NCT06878261 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Indiana: Evansville, Indianapolis
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
  NCT07363694 · Phase: Phase 2, Phase 3 · Ages: 35 Years to 80 Years · Sex: All (male and female) · Indiana: Hammond, Merrillville
• Acoustic Waveform Respiratory Evaluation
  NCT06512064 · Phase: Not applicable (e.g. observational or device study) · Ages: 8 Years to 70 Years · Sex: All (male and female) · Indiana: Indianapolis
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
  NCT07190209 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Indiana: Indianapolis
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Indiana: Hammond
• The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
  NCT07612878 · Phase: Not specified · Ages: 40 Years and older · Sex: All (male and female) · Indiana: Indianapolis
• To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
  NCT07684820 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female) · Indiana: Indianapolis
• Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD
  NCT07610395 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female) · Indiana: Valparaiso